Drug Trial News

RSS

Two-drug combo shows durable benefit in advanced kidney cancer

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

1 Aug 2025

Experimental drug found to be safe and effective in treating children with MIS-C

In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID.

30 Jul 2025

Study finds benefits of personalized ventilation in ICU care

A seven-year international, multi-centre clinical trial led by London Health Sciences Centre Research Institute (LHSCRI) and St. Michael's Hospital, a site of Unity Health Toronto, has found that a new ventilation mode called proportional assist ventilation (PAV+™) could improve outcomes for patients in the intensive care unit (ICU) who require help breathing.

24 Jul 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

Innovative immunotherapy trial opens for newly-diagnosed glioblastoma patients

A UCL-sponsored clinical trial for patients newly diagnosed with glioblastoma, an aggressive form of brain cancer, has opened at UCLH's National Hospital for Neurology and Neurosurgery and Clinical Research Facility, in memory of Baroness Margaret McDonagh.

24 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

STRIDE immunotherapy sets new benchmark for survival in advanced liver cancer

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) has shown that one in five (19.6%) participants treated with STRIDE (Single Tremelimumab Regular Interval Durvalumab) a combination of two immunotherapies, remained alive after five years of follow-up versus one in 10 (9.4%) participants treated with sorafenib, a standard treatment for uHCC when the study was designed.

23 Jul 2025

New antibody therapy offers hope for fragile patients with Fanconi anemia

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

22 Jul 2025

AI-guided patient stratification boosts Alzheimer’s trial outcomes and efficiency

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.

17 Jul 2025

UNM researchers get $1 million grant to launch early clinical trial for Alzheimer’s vaccine

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer's dementia.

15 Jul 2025

Long-term survival achieved in stage III melanoma with pre-surgery immunotherapy

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

12 Jul 2025

Teclistamab shows promising results in heavily pretreated multiple myeloma

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes.

12 Jul 2025

New chemotherapy regimen improves fertility outcomes in young Hodgkin's lymphoma patients

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their own children after treatment.

10 Jul 2025

Updated NeoVax cancer vaccine shows improved immune response in melanoma trial

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.

10 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025